FDA Clears Metagenomi’s MGX-001 for Clinical Testing

Metagenomi Therapeutics has received Food and Drug Administration approval for its investigational new drug application for MGX-001, an experimental treatment for hemophilia A. The company plans to begin a global clinical trial in the first half of 2027.

November 11, 2026, 01:43 AM 242 0

FDA Clears Metagenomi’s MGX-001 for Clinical Testing

Preclinical tests in non-human primates showed FVIII activity within the normal range, Metagenomi said. FVIII is a blood protein involved in clot formation.

The company aims to report initial clinical data in the second half of 2027. Chief Executive Jian Irish said MGX-001 could offer long-term benefit to adult and pediatric patients, describing hemophilia A as a disease with no cure.

When reusing this material a link to Money Talk is required.